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Abstract
Background: Gout prevalence increased in recent years to become one of the most common causes of
inflammatory arthritis in most industrialised countries. Comorbidities may affect the disease severity and treatment
patterns. We describe the main characteristics of gout patients, gout-related treatment patterns and prevalent
comorbidities in a managed care population.
Methods: From the large US PharMetrics Patient-Centric Database, patients aged 20-89 with at least 2 claims for a
diagnosis of gout (ICD9 274.xx) and related prescriptions between January 1, 1996 and December 31, 2008 were
included. Gout flares were ascertained during follow-up. Sex-specific multivariable Poisson regression models were
used to assess factors associated with number of flares.
Results: 177,637 gout patients were included (mean age 55.2 years; men 75.6%). Overall, more than half (58.1%)
had any of the considered comorbidities; hypertension (36.1%), dyslipidemia (27.0%) and diabetes (15.1%) being
the most common. Nonselective NSAIDs were the most commonly dispensed (in 38.7% of patients). Notably, 39%
of patients did not receive any prescription medication for gout. Patients with comorbidities were significantly
more likely to receive anti-gout prescriptions. During an acute episode the prescription of NSAIDs and colchicine
increased; and 29.9% of patients received allopurinol. The risk of flares was associated with cardiometabolic
comorbidities and older age in women (highest at age 60-69), while in men it decreased by age. Women with
these conditions were 60% more likely to have flares (incidence rate ratio, IRR 1.60;1.48-1.74), while men were 10%
(IRR 1.10; 1.06-1.13) more likely.
Conclusions: Comorbidities affected gout treatment patterns and the occurrence and frequency of acute attacks.
Cardiometabolic comorbidities, common in this patients’ population, were associated with an increased risk of
flares.
Background
Gout prevalence has been increasing in recent years and
it is currently one of the most common causes of
inflammatory arthritis in most industrialised countries
[ 1 ] .T h ei n c r e a s ei nt h ed i s e a s ep r e v a l e n c eh a sb e e n
linked to increased lifespan, dietary habits, increase in
obesity and alcohol consumption; and use of drugs that
may raise serum urate levels [1,2]. The most important
single risk factor for developing gout is a raised serum
uric acid level. Gout results from the deposition of urate
crystals in a joint, leading to an acute inflammatory
response. One acute attack may be the only manifesta-
tion, or acute inflammatory arthritis episodes (flares),
often monoarticular, may recur. If untreated this may
lead to chronic gouty arthropathy and deposition of
urate crystals in soft tissues, forming tophi.
Acute gout attacks are painful and potentially
disabling, needing immediate treatment. The optimal
therapy is directed at controlling pain and inflammation
[3,4]. Drug therapy for gout has become an important
part of the therapeutic approach to the disease, which
includes lifestyle modifications, and guidelines for its
management are available internationally [5,6]. Current
standards for first-line treatment for acute attacks
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colchicine and corticosteroids. Urate-lowering treatment
(ULT) (most commonly allopurinol) is usually recom-
mended after the acute attack has resolved.
Despite growing understanding of the disease aetiol-
ogy and risk factors involved, evidence is accumulating
that part of the patient populations is not optimally
treated and managed and continue to experience clinical
manifestations of gout [7,8]. Moreover, suggested first-
line therapies are often not well tolerated, and may be
contraindicated in some patients due to coexistent
medical problems, especially in the elderly, as the major-
ity of these patients have pre-existing conditions such as
diabetes, renal, cardiovascular or gastrointestinal dis-
eases [9,2].
The objective of this study was to describe the main
characteristics of a large population of patients with
gout, their gout-related treatment patterns and prevalent
comorbidities and to investigate the frequency and risk
factors of flares during follow-up using a managed care
population from the US.
Methods
This retrospective cohort study was conducted in the
PharMetrics Patient-Centric Database, an administrative
claims database which contains medical and pharmacy
claims for > 55 million patients from > 90 managed care
health plans in the US. Access to the PharMetrics
database requires a licence agreement and the data are
provided deidentified. Tabulations for these data do not
require ethical approval.
Records in the database are representative of the
national commercially insured population on a variety
of demographic variables, including age, gender, geo-
graphic distribution and plan type. The average member
enrolment time is 2 years. All patients aged 20-89 years
with at least 2 claims (either primary care, office visit or
emergency room visit) for a diagnosis of gout (Interna-
tional Classification of Diseases 9th Edition (ICD9) 274.
xx) between January 1, 1996 and December 31, 2008
were identified from the anonymized database. The
index date was defined as the first occurrence of a gout
claim during the study period. Patients were only
included in the study if they had been continuously
enrolled in the health plan for the period between
6 months before and one year after the index date.
Gout flares were ascertained during the follow-up per-
iod. Gout flares were defined as a claim reporting gout
as defined above, together with at least one of the fol-
lowing within one week: a) treatment with NSAIDs, col-
chicine, oral corticosteroids, or adrenocorticotropic
hormone (ACTH); b) intraarticular aspiration or injec-
tion (Current Procedural Terminology (CPT) codes
206.00, 206.05 or 206.10). Given that an untreated gout
flare can last up to a few weeks, each gout flare was esti-
mated to last 30 days and a new flare episode was
counted only if it had occurred beyond the 30-day per-
iod. The results related to number of flares included a
12 months follow-up period starting 30 days after index
date.
Gout medication treatment patterns were identified
f r o mt h ep h a r m a c yc l a i m s .U s eo fN S A I D s( s e l e c t i v e /
non-selective), colchicine, corticosteroids (oral or injec-
tions), probenecid, and allopurinol was ascertained dur-
ing a period of 12 months following the index date; and
within a week following a flare, to capture drug pre-
scription following an acute episode.
Comorbidities were identified based on the ICD9
codes, during the 6 months before the index date, for
claims with a diagnosis of congestive heart failure,
ischemic heart disease, hypertension, diabetes, cerebro-
vascular disease, dyslipidemia, chronic renal failure, gas-
trointestinal disease, haematological disease, myopathy,
osteoporosis.
Data were described using simple descriptive statistics.
Sex-specific multivariable Poisson regression models
were used to assess factors associated with number of
flares. The covariates considered in the multivariable
regression model included established risk factors, i.e.
a g ea n dh i s t o r yo fc o m o r b i d i t i es (cardiometabolic, gas-
trointestinal, haematological, myopathy, osteoporosis).
All statistical analyses were carried out using SAS
(version 9.2).
Results
Table 1 shows the main characteristics of the 177,637
gout patients included in the study (12 patients were
excluded because they had a previous diagnosis of gout
within 6 months of the index data). Mean age was 55.2
years (SD 13.1). Men represented the majority of
patients (75.6%). Overall, more than half (58.1%) had
any of the considered comorbidities; hypertension
(36.1%), dyslipidemia (27.0%), diabetes (15.1%) and
ischemic heart disease (10.2%) being the most
common.
During the 12 months following the index date, 1.2%
of patients were hospitalised at least once and 37.0%
underwent an outpatient visit. In almost one third of
patients (31.8%) the index visit was carried out at the
primary care physician office; in only 2.7% it was con-
ducted by a rheumatologist, while it was not known
who made the diagnosis in almost 60% of the cases.
Overall 32,244 patients had at least 1 acute gout epi-
sode recorded in the database during the follow-up per-
iod (mean follow-up (SD) was 2.16 (1.45) years).
According to the operational definition of flare used, in
the 12 months of follow-up after the first occurrence of
a gout claim (starting 30 days after index date) 11% of
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flares.
Table 2 shows the gout related drugs utilization for
the whole cohort and separately for men and women in
the 12 month of follow-up. Nonselective NSAIDs were
the most commonly dispensed (38.7% ever used them:
40.5% of men and 33.3% of women), followed by allo-
purinol (35.5%), corticosteroids (20.4%) and colchicine
(18.3%) in men; and corticosteroids (22.7%), allopurinol
(20.6%) and colchicine (11.8%) in women. Notably, 39%
of patients (36.9% of men and 45.3% of women) did not
receive any prescription medication for gout.
Patients with cardiometabolic comorbidities were sig-
nificantly more likely to be dispensed selective NSAIDs
(7.9% vs 5.5%), colchicine (17.6% vs 15.6%), corticoster-
oids (22.5% vs 19.1%) and allopurinol (32.6% vs 31.2%)
than gout patients with no comorbidites (all p < 0.0001
after adjusting for age). This was true for both genders.
Patients with diabetes and cardiovascular comorbidities
had similar patterns of anti-gout treatment prescrip-
tions. Compared with those with no comorbidities,
patients with renal impairment were less likely to be
dispensed nonselective NSAIDs (17.5%), and more likely
to receive allopurinol (43.9%), colchicine (27.3%) and
corticosteroids (28.3%) (all p-values < 0.0001).
Table 3 shows the gout related drugs dispensed in the
7 days after any flare. During a flare the prescription of
NSAIDs and colchicine increased. Almost a third
(29.9%) of patients received allopurinol during an acute
attack.
Patients with acute attacks were also more likely to
receive treatment within 12 months following the index
date, compared with the gout population who did not
experience flares, as shown in Table 4. In particular, the
corresponding numbers dispensed colchicine among
patients with no, 1, 2, and 3 or more flares were 12.2%,
49.9%, 66.5% and 80% respectively. 27.9% of patients
with no flares received allopurinol during the 12 months
of follow-up, vs. 60.8%, 77.8% and 87.8% of patients
with 1, 2, and 3 or more flares respectively. Patients
w i t h3o rm o r ef l a r e sw e r ea l s om o r el i k e l yt ob ed i s -
pensed corticosteroids (70.6%) than those with 1 flare
(45.7%) (Table 4).
Table 5 shows the results of the multivariable analysis.
The risk of flares was associated with older age in
women (highest at age 60-69), while in men it decreased
by age. It was also positively associated with cardiometa-
bolic comorbidities. Women with these conditions were
60% more likely to have flares (incidence rate ratio, IRR
1.60;1.48-1.74), while men were 10% more likely (IRR
1.10; 1.06-1.13). Gastrointestinal diseases were negatively
associated with flares in women (IRR 0.86; 0.78-0.96)
while a positive association was seen in men (IRR 1.07;
1.02-1.13). (Table 5).
When use of diuretics was entered in the model it
showed a positive association with flares both in women
(IRR 4.34; 4.03-4.68) and in men (IRR 1.9 1; 1.50-1.98)
(data not shown).
Discussion
This study, based on a US administrative claims data-
base, examined prescription patterns, comorbidities and
flares determinants in a very large population of gout
patients. In line with current guidelines [5], NSAIDs and
Table 1 Demographic characteristics of gout patients (N
= 177,637)
N%
Male gender 134,333 75.6%
Age in categories
20-49 59,371 33.4%
50-59 54,612 30.7%
60-69 37,016 20.8%
70-79 19,790 11.1%
80-89 6,848 3.9%
Comorbidities:
Cardiometabolic 91,203 51.3%
Congestive Heart Failure 7,467 4.2%
Ischemic Heart Disease 18,066 10.2%
Hypertension 64,094 36.1%
Conduction and rhythm disorder 12,034 6.8%
Cerebrovascular disease 4,934 2.8%
Peripheral arterial disease 6,271 3.5%
Chronic renal impairment 5,718 3.2%
Dyslipidemia 47,960 27.0%
Diabetes 26,818 15.1%
Gastrointestinal 14,224 8.0%
Gastrointestinal 11,836 6.7%
Hepatic disorders 2,718 1.5%
Pancreatic disorders 501 0.3%
Haematological (Anemia) 3,829 2.2%
Myopathy 159 0.1%
Arthritis 25,516 14.4%
Osteoporosis 5,044 2.8%
Any comorbidity 103,281 58.1%
Gout diagnosis recorded by:
Primary care physician 56,512 31.8%
Rheumatologist 4,731 2.7%
Emergency visit 10,482 5.9%
Other or Unknown specialty 105,912 59.6%
Hospitalized in 12 months follow-up (at least once) 2,119 1.2%
Outpatient visit in 12 months follow-up (at least once) 65,665 37.0%
Number of flares in 12 months follow-up:
0 158,268 89.1%
1 15,893 9.0%
2 2,790 1.6%
3 or more 686 0.4%
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during an acute attack. However our data suggest that
somewhat suboptimal treatment and management may
occur in clinical practice: almost a third of patients
received ULT during an acute attack and 39% of
patients did not receive any prescription medication for
gout. Cardiometabolic comorbidities in particular were
associated with gout treatment patterns and were also
associated with a high burden of disease, as reflected by
an increased risk of flares.
Gout treatment has been shown to be suboptimal in
two studies from the US [10,11] and a study from the
UK [12]. According to our data, gout treatment was
relying mostly on traditional treatment means such as
NSAIDs to control inflammation and pain. Corticoster-
oids and colchicine were dispensed in about a fifth of
patients while ULT, recommended as the treatment to
prevent further acute attacks, was dispensed in less than
a third of all gout patients and probenecid was seldom
dispensed. Probenecid use was also described as infre-
quent in a study based on US ambulatory care data [13].
Here the authors, basing their study on a national prob-
ability sample survey of physicians-patients encounters,
showed a larger overall utilisation of allopurinol in
patients with gout than in our study. Differences in esti-
mates may be related to differences in data collection
methods and patients characteristics (e.g. age and geo-
graphic location). For example, the age distribution of
this patient population appeared to be younger com-
pared to other studies. On average, only 12% of the
PharMetrics population was aged 60-89. This may make
the results of our study less generalizable to the gout
population overall, however consistent with the age dis-
tribution in other health care plans [14].
NSAIDs have been reported as the drug of first choice
to treat acute gout attacks in the US [2] and in other
Table 2 Gout related treatment patterns overall and by presence of comorbidities
Gout-related medication Ever use during 1 year after gout diagnosis
All No comorbidities
(n = 74,356)
Cardiometabolic§
(n = 64,385)
Diabetes
(n = 26,818)
Chronic renal impairment
(n = 5,718)
ALL n % n % n % p-value* n % n %
NSAIDS 74,055 41.7% 32,701 44.0% 25,994 40.4% 0.022 9,592 35.8% 1,134 19.8%
selective 12,455 7.0% 4,102 5.5% 5,077 7.9% < .0001 1,942 7.2% 219 3.8%
nonselective 68,826 38.7% 31,167 41.9% 23,765 36.9% 0.173 8,660 32.3% 1,001 17.5%
Colchicine 29,686 16.7% 11,595 15.6% 11,327 17.6% < .0001 4,950 18.5% 1,559 27.3%
Corticosteroids 37,224 21.0% 14,182 19.1% 14,476 22.5% < .0001 5,153 19.2% 1,617 28.3%
Probenecid 2,510 1.4% 1,108 1.5% 901 1.4% 0.249 331 1.2% 58 1.0%
Allopurinol 56,544 31.8% 23,215 31.2% 20,971 32.6% < .0001 9,183 34.2% 2,512 43.9%
No treatment 69,241 39.0% 29,202 39.3% 24,938 38.7% < .0001 10,669 39.8% 2,171 38.0%
FEMALES N = 43,304 N = 12,387 N = 17,418 N = 9,381 N = 2,025
NSAIDS 16,183 37.4% 4,641 37.5% 6,464 37.1% < .0001 3,279 35.0% 368 18.2%
selective 3,815 8.8% 911 7.4% 1,643 9.4% < .0001 769 8.2% 77 3.8%
nonselective 14,423 33.3% 4,255 34.4% 5,684 32.6% 0.000 2,899 30.9% 320 15.8%
Colchicine 5,096 11.8% 890 7.2% 2,312 13.3% < .0001 1,558 16.6% 483 23.9%
Corticosteroids 9,831 22.7% 2,438 19.7% 4,213 24.2% < .0001 1,954 20.8% 575 28.4%
Probenecid 441 1.0% 96 0.8% 195 1.1% 0.359 115 1.2% 27 1.3%
Allopurinol 8,905 20.6% 1,676 13.5% 4,006 23.0% < .0001 2,692 28.7% 834 41.2%
No treatment 19,637 45.3% 6,200 50.1% 7,693 44.2% < .0001 3,991 42.5% 816 40.3%
MALES N = 134,333 N = 61,969 N = 46,967 N = 17,437 N = 3,693
NSAIDS 57,872 43.1% 28,060 45.3% 19,530 41.6% 0.575 6,313 36.2% 766 20.7%
selective 8,640 6.4% 3,191 5.1% 3,434 7.3% < .0001 1,173 6.7% 142 3.8%
nonselective 54,403 40.5% 26,912 43.4% 18,081 38.5% 0.012 5,761 33.0% 681 18.4%
Colchicine 24,590 18.3% 10,705 17.3% 9,015 19.2% < .0001 3,392 19.5% 1,076 29.1%
Corticosteroids 27,393 20.4% 11,744 19.0% 10,263 21.9% < .0001 3,199 18.3% 1,042 28.2%
Probenecid 2,069 1.5% 1,012 1.6% 706 1.5% 0.260 216 1.2% 31 0.8%
Allopurinol 47,639 35.5% 21,539 34.8% 16,965 36.1% < .0001 6,491 37.2% 1,678 45.4%
No treatment 49,604 36.9% 23,002 37.1% 17,245 36.7% < .0001 6,678 38.3% 1,355 36.7%
§ Cardiometabolic disease include congestive heart failure, ischaemic heart disease, hypertension, cerebrovascular disease, peripheral arterial disease,
dyslipidemia.
* P-value from logistic model with drug as outcome associated to cardiometabolic comorbidities vs no comorbidities adjusting for age in categories (20-49, 50-
59, 60-69, 70-79, 80-89).
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with gastrointestinal, renal and cardiovascular effects
and it was not surprising that in our study patients with
cardiometabolic comorbidities, and in particular those
with chronic renal impairment, had the prescription of
NSAIDs greatly reduced. It is notable that almost two
fifths of patients did not receive any prescription within
12 months from the index date. These patients may
have had fewer flares, i.e. less severe manifestation of
the disease, may have had medication still at home, or
been able to purchase over the counter medications to
reduce their symptoms, since non-prescription medica-
tions would not be recorded in the database.
G i v e nt h a th y p e r u r i c e m i ai st h em o s ti m p o r t a n ts i n -
gle risk factor for gout, the long-term management of
hyperuricemia to prevent further attacks and complica-
tions of the disease is an important component of the
therapeutic regimen. The use of ULT is recommended
after the acute episode has subsided [5], however
according to our data almost a third of patients
received a prescription of allopurinol during an acute
attack. An increased number of flares during the 12
months from the first occurrence of a gout claim
seemed to have resulted in more aggressive treatment
patterns. In particular, more than three times as many
patients with 3 or more flares were dispensed corticos-
teroids or allopurinol compared with patients with no
flares. This may reflect the fact that in patients with
more severe disease (using number of flares as an
indicator of disease severity) the available therapeutic
regimen was not adequate to prevent further acute
attacks, and the treating physician had to step up the
treatment.
Table 4 Treatment patterns: patients with no flares and with flares occurring during follow-up of 12 months
(N = 19,369)
Ever during 12 months No flares Total (any flare) 1 flare 2 flares 3 flares
after index date (n = 19,369) (n = 15,893) (n = 2,790) (n = 686)
n% n % n% n % n %
NSAIDS 58325 36.9% 15730 81.2% 12821 80.7% 2338 83.8% 571 83.2%
selective 10110 6.4% 2345 12.1% 1795 11.3% 430 15.4% 120 17.5%
nonselective 53750 34.0% 15076 77.8% 12278 77.3% 2245 80.5% 553 80.6%
Colchicine 19353 12.2% 10333 53.3% 7929 49.9% 1855 66.5% 549 80.0%
Corticosteroids 28379 17.9% 8845 45.7% 6695 42.1% 1666 59.7% 484 70.6%
Probenecid 1781 1.1% 729 3.8% 503 3.2% 174 6.2% 52 7.6%
Allopurinol 44110 27.9% 12434 64.2% 9662 60.8% 2170 77.8% 602 87.8%
No treatment 69241 43.7% 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Table 5 Poisson multivariate regression model for
number of flares during follow-up of 12 months by sex
Females
(N = 43,304)
Males (N = 134,333)
IRR 95% CI p-
value
IRR 95% CI p-
value
Age < 50 1.00 (ref.) 1.00 (ref.)
50 -
59
1.66 (1.49,
1.85)
<
.0001
0.83 (0.80,
0.85)
<
.0001
60 -
69
1.93 (1.73,
2.16)
<
.0001
0.76 (0.73,
0.79)
<
.0001
70 -
79
1.69 (1.51,
1.90)
<
.0001
0.56 (0.53,
0.60)
<
.0001
80 -
89
1.31 (1.12,
1.52)
0.001 0.53 (0.48,
0.59)
<
.0001
Comorbidities:
Cardiometabolic* 1.60 (1.48,
1.74)
<
.0001
1.10 (1.06,
1.13)
<
.0001
Diabetes 1.48 (1.35,
1.63)
<
.0001
0.97 (0.93,
1.02)
0.262
Gastrointestinal 0.86 (0.78,
0.96)
0.005 1.07 (1.02,
1.13)
0.011
Hematological 1.03 (0.88,
1.20)
0.720 0.94 (0.84,
1.06)
0.340
Myopathy 1.21 (0.50,
2.91)
0.670 0.84 (0.50,
1.42)
0.509
Osteoporosis 0.88 (0.78,
1.00)
0.044 1.11 (0.99,
1.25)
0.076
IRR = Incidence rate ratio.
* Cardiometabolic disease include congestive heart failure, ischaemic heart
disease, hypertension, cerebrovascular disease, peripheral arterial disease,
dyslipidemia.
Table 3 Treatment patterns for treatment of flares
occurring at any time during the study period
Gout drugs within 7 days of flare
(any flare) n = 32,244
n%
NSAIDS 21,633 67.1%
selective 1,283 4.0%
nonselective 20,748 64.3%
Colchicine 12,847 39.8%
Corticosteroids 8,598 26.7%
Probenecid 420 1.3%
Allopurinol 9,644 29.9%
No treatment 0 0.0%
Primatesta et al. BMC Musculoskeletal Disorders 2011, 12:103
http://www.biomedcentral.com/1471-2474/12/103
Page 5 of 7The association between cardiovascular disease and
gout, including significant cardiovascular mortality risk,
is well recognised [15-17]. EULAR guidelines therefore
recommend screening for cardiovascular risk and treat-
ing comorbid conditions in gout patients [5]. Our study
demonstrated that cardiometabolic comorbidities were
frequent in this patient population. They impacted the
prescription patterns, since these patients were more
likely to be prescribed corticosteroids, colchicine, selec-
tive NSAIDs and allopurinol than patients with no
comorbidities. The increased use of selective NSAIDs in
patients with cardiometabolic comorbidities is somewhat
counterintuitive given their potential cardiovascular risk
(although data collection partly preceded recent cardio-
vascular concerns), even though the EULAR guidelines
are still open on this issue [5]. Regarding the increased
use of allopurinol in patients with cardiometabolic
comorbidities, this may also be considered to go against
clinical judgement, in particular considering its potential
toxicity in patients with impaired renal function and the
potential for drug interaction (e.g. warfarin). Whether
allopurinol should be prescribed at reduced dosage in
patients with impaired renal function remains however
still controversial [5]. These patients were also at
increased risk of flares. The use of diuretics is a recog-
nised risk factor for gout. Although contraindicated [5],
these medications are commonly prescribed in this
patients’ population, and this may increase their risk of
flares.
Women with gastrointestinal diseases were at reduced
risk of flares while in men the association was in the
opposite direction. This observation has not been made
before and should get further consideration in future
studies.
Patients with renal impairment were less likely to be
prescribed NSAIDs than gout patients without comor-
bidities, and more likely to receive allopurinol, colchi-
cine and corticosteroids. It is recommended that these
patients receive a lower dose of allopurinol given that
they are at increased risk of toxic effects [14]. Providing
adequate information to these patients regarding the
risks and benefits at different dosages would be
advisable.
Limitations of a study based on an administrative
claims database need to be considered. Firstly, these
data only apply to patients with a commercial insurance
and these findings may therefore not be generalisable to
gout patients without commercial insurance. Further,
the diagnosis of gout was not confirmed using medical
record review. To increase the sensitivity and specificity
of the gout identification algorithm, a patient was only
classified as a gout patient if two distinct medical
encounters with a diagnosis of gout were present in the
record. This would reduce the potential for including in
the study patients without gout. Currently there is no
validated epidemiological definition of gout flare, and
although we followed the definition used by other
authors (cfr e.g. ref [14]), based on clinical measure-
ments, we expect that some errors of sensitivity (failure
to identify true gout flares) and specificity (identification
of subjects who did not experience gout flares) may be
inherent in the definition. Specifically, some patients
may, when starting ULT, have received NSAIDs, colchi-
cine and, less commonly, steroids as prophylaxis against
acute attacks and this may have lead to an overestima-
tion of flares. However, by excluding those who com-
menced allopurinol treatment within 7 days before a
flare the number of patients with flares would not have
changed substantially (19,267 vs 19,369 observed).
It is also recognised that many patients with gout
flares do not consult their physician [11], and may self-
manage acute episodes. This is likely to be the case in
the present study, given that the risk of gout flares
reported over one year follow-up (10.9%) is lower than
what other studies have shown [18]. It was also not pos-
sible to verify that the drugs included were dispensed
for gout and to assess adherence to the prescribed treat-
ment. Nevertheless, epidemiological studies such as the
present one, which included a very large number of
patients with gout, with a large US geographic distribu-
tion, can improve our understanding of management of
gout in real world settings.
Conclusions
In conclusion, results from the analysis of data from this
large administrative claims database are supporting sug-
gestions from other studies [10-12], i.e. that suboptimal
treatment and management of gout may occur in clini-
cal practice. In addition, cardiometabolic comorbidities,
common in this patient population, were associated with
a higher burden of disease, as reflected by an increased
risk of flares.
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